2.5 behazine combadiere
-
Upload
association-lir -
Category
Health & Medicine
-
view
765 -
download
0
Transcript of 2.5 behazine combadiere
CEA CHRU
CNRS
CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
1CEA CHRU
CNRS
CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
Skin targeting for vaccine efficacy
Laboratory of « Immunity and Infection »INSERMParis, France
Behazine COMBADIERE, PhDDirector of research INSERM
CEA CHRU
CNRS
CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
FONDAMENTAL QUESTIONS AND NEW HOPES FOR VACCINATION
B cells
CD4 T cells
CD8 T cells
Dendritic cells
Intensity
Quality(T cells: cytokine released,
cytotoxicity, B cells: IgG, IgA)
Persistence of Memory
Localization (mucosa, skin, liver)
1- Vaccination for whom?Defining the target population History of infection and multiplicity of vaccination Other diseases in the population
2- What type of immunity ?Defining the correlates of protection differs depending of the pathogens
3- How?Adapting the route of immunization bio-diversity of antigen-presenting cells (AP Skin, Mucosa sites
CEA CHRU
CNRS
CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
SKIN TARGETING OF APC DICTATES IMMUNOLOGICAL OUTCOMES
B cells
CD4 T cells
CD8 T cells
Dendritic cells
Lymph nodesStratum corneum
Epidermis
Dermis
Hypodermis
Lymphatic and blood capillary vessels
Dermal-epidermal junction
HAIR FOLLICLE
Blood vessels
Leukocytes recruitment(neutrophils,
monocytes, pDC)
Lymphatic vessels
Differential targeting of antigen-presenting cells
dictates the immunological outcomes
(intensity, quality, localization)
Langerhans cells
Dermal DC
Lymph nodeMicro-
environments
Lymph nodeMicro-
environments
CEA CHRU
CNRS
CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
HAIR FOLLICLE TARGETING OF COMPOUNDS TO LANGERHANS CELLS
Stratum corneum
Hair fibre
Follicular cast
+ cyanoacrylate glue + follicular casts+ ca. 30% of stratum corneum
Vogt et al. J Invest Dermatology 2006 and Mahe J Invest Dermatology 2008
Stratum corneum
Epidermis
Dermis
Hypodermis
Lymphatic and blood capillary vessels
CEA CHRU
CNRS
CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
SUITABLE SIZE OF VACCINE COMPOUNDS INTO FOLLICULAR DUCTS
5
37°C
Skin purified human CD1a+ cells (+40nm)
1500-700 nm
200 nm
40 nm
Suitable size for Langerhans cells up-take of vaccine :
biodegradable or solid nanoparticles, virus like particles, small
viruses, DNA, protein/peptide-carrier
CEA CHRU
CNRS
CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
Influenza-specific CD8
PROOF OF CONCEPT: PHASE I TRIAL OF AN INFLUENZA VACCINE
Influenza-specific CD4
Vogt et al. J Immunol 2008 and Combadiere et al Plos One 2010 TC route
IM route
Hair follicle Langerhans cells favors CD8 responses
and also mucosal immunity but not IgG responses
CEA CHRU
CNRS
CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
FROM HUMANIZED MICE TO CLINICAL TRIALS
“tailor-cut” immunization strategies could be proposed for
infectious diseases:
HIV, Malaria, Tuberculosis, emerging diseases and cancer
EU-FP7 large-scale coordination : CUT’HIVAC project 2010-2014
Human skin Explants
Human immune cells
Immunodeficient mice
CLINICAL TRIALSPre-clinical modelsHumanized mice
CEA CHRU
CNRS
CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
PERSPECTIVES
Alternative methods of vaccination against infectious diseases to increase vaccine efficacy and allow a “tailor-cut” immune response
Understanding skin immunological role for initiation and maintenance of immunity to infectious diseases
Translation of basic research using innovative preclinical models into clinical trials
5 Phase I/II/IIa clinical trials are planned for 2011-2014:
o Preventive and therapeutic HIV vaccine (3 trials): DNA-GTU® technology (FIT-Biotech) by TC, ID, IM or combined routes
o Influenza vaccination in adults and in elderly (2 trials) : trivalent influenza vaccine by TC, ID and IM routes